Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,065 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, Cohort 3 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297
View directory record Official record
Conditions
Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions
BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 5, 2026, 3:53 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 5, 2026, 3:53 AM EDT
Terminated Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

NCT02593851
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Virus Diseases
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
1 Month to 24 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 5, 2026, 3:53 AM EDT
Terminated Phase 2 Interventional Results available

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02927080
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
ACE-083, ACE-083 or placebo
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

NCT05890105
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07853578, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

NCT01294410
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Anti-IP-10 Antibody
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
La Jolla, California • Santa Monica, California • Wheat Ridge, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 5, 2026, 3:53 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of IGM-6268 in Healthy Volunteers

NCT05160402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IGM-6268, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

NCT01431898
View directory record Official record
Conditions
Hepatitis C
Interventions
GS-9669 tablets, Placebo to Match GS-9669 tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

NCT01576328
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mesenchymal Precursor Cells (MPCs)
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 5, 2026, 3:53 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

NCT05327816
View directory record Official record
Conditions
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions
RSV preF-based Vaccine, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
11
States / cities
Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 5, 2026, 3:53 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

NCT05731544
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
36
States / cities
Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

NCT02918929
View directory record Official record
Conditions
Presumptive NAFLD
Interventions
EDP 305, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of CTS21166 to Treat Alzheimer Disease

NCT00621010
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CTS21166 (ZPQ-21166)
Drug
Lead sponsor
CoMentis
Industry
Eligibility
22 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC4703 in Healthy Volunteers

NCT05552274
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
ECC4703, Placebo
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study of XOMA 3AB

NCT01357213
View directory record Official record
Conditions
Botulism
Interventions
XOMA 3AB, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 5, 2026, 3:53 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479
View directory record Official record
Conditions
Migraine
Interventions
MEDI0618, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 5, 2026, 3:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

NCT07215923
View directory record Official record
Conditions
Thromboangiitis Obliterans (Buerger's Disease)
Interventions
ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g), Placebo
Biological · Other
Lead sponsor
Antidote Therapeutics, Inc
Industry
Eligibility
23 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 5, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

NCT04364789
View directory record Official record
Conditions
Healthy
Interventions
TT-00920, Placebos
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 5, 2026, 3:53 AM EDT